Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma.
BDC
CA125
MSLN
cholangiocarcinoma
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
11
12
2020
accepted:
15
02
2021
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
ppublish
Résumé
Recent studies have suggested that the interaction of mesothelin (MSLN) and cancer antigen 125 (CA125) enhances tumor metastases. The aim of the present study was to clarify the impact of MSLN and CA125 co-expression on the prognosis of patients with extrahepatic bile duct carcinoma (BDC). Tissue samples from patients who underwent surgical resection between 2007 and 2015 for perihilar or distal BDC were immunohistochemically examined. The expression levels of MSLN and CA125 in tumor cells were analyzed. The expression in <50% and ≥50% of the total tumor cells were defined as low- and high-level expression, respectively. Tissue samples were obtained from 31 patients with perihilar BDC and 43 patients with distal BDC. Lymph node metastases were associated with MSLN and CA125 co-expression in patients with perihilar BDC (P=0.002), while there was no association between lymph node metastasis and co-expression in patients with distal BDC (P=0.362). MSLN and CA125 co-expression was associated with a worse overall survival rate in patients with perihilar BDC (5-year overall survival rate, co-expression positive vs. negative, 24 vs. 63%; P=0.038). To the best of our knowledge, the present study is the first to report an association between co-expression of MSLN and CA125 with a poor prognosis in patients with perihilar BDC. The current findings suggested that the significance of co-expression differed according to the BDC location.
Identifiants
pubmed: 33841575
doi: 10.3892/ol.2021.12675
pii: OL-0-0-12675
pmc: PMC8020376
doi:
Types de publication
Journal Article
Langues
eng
Pagination
414Informations de copyright
Copyright: © Takihata et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Med. 2020 Feb;9(4):1335-1348
pubmed: 31876990
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1461-1467
pubmed: 28756216
Am J Surg Pathol. 1992 Mar;16(3):259-68
pubmed: 1599018
J Biol Chem. 2009 Feb 6;284(6):3739-49
pubmed: 19075018
Sci Rep. 2013;3:1870
pubmed: 23694968
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Br J Cancer. 2012 Jun 26;107(1):137-42
pubmed: 22644300
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
World J Surg Oncol. 2012 Jun 08;10:106
pubmed: 22681770
Clin Cancer Res. 2005 May 15;11(10):3814-20
pubmed: 15897581
Cancer Sci. 2012 Apr;103(4):739-46
pubmed: 22320398
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Hum Pathol. 2005 Jun;36(6):655-64
pubmed: 16021572
Int Surg. 2013 Apr-Jun;98(2):164-9
pubmed: 23701154
Mol Cancer. 2006 Oct 26;5(1):50
pubmed: 17067392
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42
pubmed: 15217923
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
Ann Gastroenterol Surg. 2019 May 22;3(4):378-389
pubmed: 31346577
Pancreas. 2011 Nov;40(8):1276-82
pubmed: 21775916
Hum Pathol. 2019 Oct;92:91-100
pubmed: 31401234
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
J Gastroenterol. 2014 Jan;49(1):81-92
pubmed: 23512344
Int J Oncol. 2012 Dec;41(6):2109-18
pubmed: 23064529